Metagenomi Therapeutics vs Relay Therapeutics
MGX and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGX and RLAY compare
Relay Therapeutics is the larger company, worth 152 times as much as Metagenomi Therapeutics ($4.0B against $26.1M).
Relay Therapeutics scores higher on the StockData Score (10 against 6 for Metagenomi Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGX | RLAY |
|---|---|---|
| Size and price | ||
| Market cap | $26.1M | $4.0B |
| Share price | $0.692 | $18.09 |
| Change, 1 year | −62.8% | 193% |
| Change, 5 years | – | −47.5% |
| Beta (5Y) | 1.28 | 1.94 |
| Employees | 119 | 192 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 383× |
| P/B | 0.3× (better) | 4.8× |
| FCF yield | −320% | – |
| Growth | ||
| Revenue growth (TTM) | – | 23.9% |
| Revenue growth, 5Y average | – | −28.6% |
| Profitability | ||
| Operating margin | – | −3095% |
| Net margin | – | −2837% |
| Return on equity | −69.4% | −41.2% (better) |
| Return on invested capital | – | −41.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.43 | 14.62 (better) |
| Altman Z-score | −4.66 | 25.18 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 16.6% | 113% |
| Held by insiders | 10.4% | 24.5% |
| Insider net buying, 12 months | −$9.7K (better) | −$129M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 3.9% | 26.4% |
Go deeper
- MGX stock overview
- MGX income statement
- MGX valuation and score
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.